Marksans Pharma share news, announcements and annual reports
NSE: MARKSANSBSE: 524404Pharmaceuticals & BiotechnologySmall Cap
Marksans Pharma Limited · Formerly Tasc Pharmaceuticals · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1994 on BSE, Jan 2002 on NSE
Last close ₹305.20up ₹5.10 (1.70%)BSE ₹305.20
Share price at the NSE close on 28 Oct 2026. Previous close ₹300.10.
28 Oct: open ₹301.10, high ₹308.25, low ₹298.65
52-week range of traded prices to 28 Oct 2026
₹155.00Low, 30 Mar 2026₹350.95High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹13,831 Cr592nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.76
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.57
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 17.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 14,05,30048.0% delivered
Marksans Pharma disputes and clarifications
11 filed, newest first.
Apr 2022
11 Apr · Legal
The exchange asked on 8 Apr 2022
Jun 2021
17 Jun · Legal
Exchange has sought clarification from Marksans Pharma Limited with respect to announcement dated 15-Jun-2021, regarding outcome of its Board meeting held on Jun 15, 2021. On basis of above the Company is required to clarify following: 1. Amendments to Memorandum and/or Articles of association of listed entity, in brief.The response of the Company is awaited.
Dec 2019
18 Dec · Legal
The exchange asked on 17 Dec 2019
Jul 2019
19 Jul · Legal
Exchange has sought clarification from Marksans Pharma Limited with respect to announcement dated 11-Jul-2019, regarding Appointment of Mr Abhinna Sundar Mohanty as Independent Director of the company. On basis of above the Company is required to clarify following: 1. Date of appointment of Mr Abhinna Sundar Mohanty. The response of the Company is awaited.
Feb 2019
1 Feb · Legal
Exchange has sought clarification from Marksans Pharma Limited with respect to announcement dated 24-Jan-2019, Change in Director(s) of the company. This is to inform you that the Board of Directors of the Company at its meeting held today i.e. 24th January, 2019, has appointed Mr. Varddhman Vikramaditya Jain (DIN: 08338573) as a Director of the Company with effect from 24th January, 2019 to fill the casual vacancy caused by the resignation of Dr. Vinay Gopal Nayak. Further, the Board of Directors at its meeting held today i.e. 24th January, 2019, has also appointed Mr. Varddhman Vikramaditya Jain (DIN: 08338573) as a Whole-time Director of the Company in the Professional Executive Director category to hold office for a period of Three (3) years with effect from 24th January, 2019.". On basis of above the Company is required to clarify following: 1. Disclosure of relationships between directors (in case of appointment of a director)The response of the Company is awaited.
Aug 2018
30 Aug · Legal
Exchange has sought clarification from Marksans Pharma Limited with respect to announcement dated 25-Aug-2018, regarding " Marksans Pharma Limited has informed the Exchange regarding Board meeting held on August 25, 2018.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment); 2. Reason for change viz. appointment, resignation, removal, death or otherwise; The response of the Company is awaited.
Dec 2007
3 Dec · Legal
With regard to the news published in the leading news paper regarding proposed acquisition by the Company of UK based OTC firm, this is to clarify that the Company is looking for inorganic growth opportunity in India as well as outside India. For the same, Company is in the process of dialogues and participation in the bidding processes. Company has also appointed, various Investment banking firms for the same purpose. However, so far, company has not entered into any definitive share subscription agreement for the acquisition.